

Oscar Juan

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6115091/oscar-juan-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

26

papers

810

citations

12

h-index

28

g-index

32

ext. papers

973

ext. citations

5

avg, IF

3.64

L-index

#	Paper	IF	Citations
26	Utility of Next-Generation Sequencing in the Reconstruction of Clonal Architecture in a Patient with an EGFR Mutated Advanced Non-Small Cell Lung Cancer: A Case Report. <i>Diagnostics</i> , 2022 , 12, 1266 ^{3.8}		0
25	Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation. <i>Cancers</i> , 2021 , 13,	6.6	2
24	Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus. <i>Clinical and Translational Oncology</i> , 2021 , 23, 1304-1313	3.6	0
23	Endothelin-1-Mediated Drug Resistance in -Mutant Non-Small Cell Lung Carcinoma. <i>Cancer Research</i> , 2020 , 80, 4224-4232	10.1	4
22	Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital. <i>Cancers</i> , 2019 , 11,	6.6	8
21	CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC. <i>Cancer Research</i> , 2019 , 79, 4439-4452	10.1	23
20	Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients. <i>Clinical and Translational Oncology</i> , 2018 , 20, 1072-1079	3.6	34
19	Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. <i>Clinical Lung Cancer</i> , 2018 , 19, 213-220.e4	4.9	12
18	Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2017 , 9, 201-216	5.4	22
17	Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017 , 18, 595-606	4.9	34
16	Translating cancer epigenomics into the clinic: focus on lung cancer. <i>Translational Research</i> , 2017 , 189, 76-92	11	26
15	Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017 , 18, 96-99	4.9	9
14	Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer. <i>ClinicoEconomics and Outcomes Research</i> , 2017 , 9, 31-38	1.7	13
13	Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , 2016 , 17, 1643-1652	21.7	412
12	Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07. <i>Anticancer Research</i> , 2016 , 36, 6647-6653	2.3	6
11	Intercalated Dosing Schedule of Erlotinib and Docetaxel as a Therapeutic Strategy to Avoid Antagonism and Optimize Its Benefits in Advanced Non-Small-Cell Lung Cancer. A Randomized Phase II Clinical Trial. <i>Clinical Lung Cancer</i> , 2015 , 16, 193-9	4.9	12
10	Atrial flutter and myocardial infarction-like ECG changes as manifestations of left ventricle involvement from lung carcinoma. <i>Clinical and Translational Oncology</i> , 2008 , 10, 125-7	3.6	6

9	Measurement and impact of co-morbidity in elderly patients with advanced non-small cell lung cancer treated with chemotherapy. A phase II study of weekly paclitaxel. <i>Acta Oncologica</i> , 2007 , 46, 367-73	3.2	17
8	Megestrol acetate-probably less effective than has been reported!. <i>Journal of Pain and Symptom Management</i> , 2005 , 30, 4; author reply 5-6	4.8	8
7	Influence of the cyto-protective agent amifostine on the pharmacokinetics of low-dose Paclitaxel. <i>Chemotherapy</i> , 2005 , 51, 200-5	3.2	1
6	Ifosfamide-induced psychosis. <i>Acta Oncologica</i> , 2004 , 43, 119-20	3.2	4
5	Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. <i>Cancer</i> , 2003 , 97, 2180-6	6.4	87
4	Weekly paclitaxel in the treatment of metastatic and/or recurrent non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2002 , 44 Suppl, S31-41	7	7
3	Low-dose weekly paclitaxel as second-line treatment for advanced non-small cell lung cancer: a phase II study. <i>Japanese Journal of Clinical Oncology</i> , 2002 , 32, 449-54	2.8	21
2	A randomized, crossover comparison of standard-dose versus low-dose lenograstim in the prophylaxis of post-chemotherapy neutropenia. <i>Supportive Care in Cancer</i> , 2001 , 9, 241-6	3.9	8
1	Prognostic factors in patients with isolated recurrences of breast cancer (stage IV-NED). <i>Breast Cancer Research and Treatment</i> , 1999 , 53, 105-12	4.4	16